The authors examined two observational studies citing target trial emulation that linked GLP-1 receptor agonists with lower cancer risk. Both counted patients as exposed after a second prescription but started follow-up at the first. Monte Carlo simulation reproduced these designs, with 500 replications of 5,000 people and a true hazard ratio of 1.0. Varying the gap between prescriptions gave hazard ratios of 0.72 to 0.39 over longer follow-up, 0.85 to 0.60 over shorter. Aligning eligibility, treatment assignment and time zero removed the bias and recovered hazard ratios centred on 1.0. The work uses simulated data only and does not re-analyse the original patient records.
Why it is interesting: Recent observational studies reported large protective associations between GLP-1 receptor agonists and cancer. This simulation shows similar estimates arise when exposure is defined after time zero, with no true effect.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.